The new JAMA Surgery review, released on January 8 2025, offers surgeons and medical researchers a straightforward roadmap for using artificial intelligence, chatbots, and large language models (LLMs) in every stage of a study. Rather than getting lost in technical jargon, the guide walks readers through real‑world examples—showing how AI can help design experiments, clean messy data, generate clear visualizations, and even draft manuscript sections. It also highlights common pitfalls, such as bias in training data and the importance of transparent reporting, so clinicians can avoid missteps that could affect patient care. Practical tips include selecting the right AI tool for a specific task, integrating chat‑based assistants into literature reviews, and using LLMs to summarize complex findings for multidisciplinary teams. The authors stress ethical considerations, data privacy, and the need for peer‑reviewed validation of AI‑generated results. By the end of the guide, surgeons will feel confident leveraging cutting‑edge technology to speed up research, improve accuracy, and communicate their discoveries more effectively—all without needing a PhD in computer science.
Read moreChina’s drug regulators say the country is on track to roll out at least five blockbuster medicines in the next five years and capture a quarter of the world’s first‑in‑class drugs by 2030. In the first half of this year the National Medical Products Administration approved 59 innovative medicines and 51 cutting‑edge medical devices, including 13 drugs that use brand‑new mechanisms or targets. Chinese firms are also speeding up overseas deals – licensing agreements now total more than $120 billion, up 36 % year‑on‑year, with upfront payments topping $10 billion. Yet experts warn that true breakthrough innovation remains limited. Many projects still chase incremental improvements, leading to a homogenous pipeline. To change that, the new five‑year plan puts “original innovation capacity” at the top of the agenda, demanding that China’s share of global first‑in‑class drugs reach at least 25 % by 2030. The plan spotlights high‑impact areas such as infectious, chronic, rare and pediatric diseases, and backs biotech fields like antibody and recombinant protein drugs, next‑generation conjugates, cell‑ and gene‑therapy, and novel vaccines. It also calls for AI, quantum computing, super‑computing and new manufacturing models to turbo‑charge drug discovery, while accelerating the domestic production of imported medicines, expanding generics and biosimilars, and improving patient access to high‑value treatments.
Read moreChina’s biotech sector is rapidly shifting from a domestic talent‑recruitment story to a full‑blown global export engine. In the past few years, returning scientists and new start‑ups have driven a wave of innovative medicines, with companies like BeOne Medicines and WuXi AppTec leading the charge. 2025 saw more than 150 outbound licensing deals worth over $130 billion, and the country’s pipeline now accounts for roughly 30 % of the world’s new‑drug candidates. Nearly half of all molecules entering human trials this year originated from Chinese firms, according to Goldman Sachs research. Regulatory reforms have helped accelerate this growth. New “Opinions” from the State Council and updated NMPA guidelines make it easier to approve drugs and accept overseas clinical data. The BIOSECURE Act and related legal changes also opened doors for Chinese firms to partner with U.S. companies. Financing has kept pace: equity investment in China’s biotech hit about ¥250 billion in 2021, while Hong Kong’s Chapter 18A listing rules have allowed unprofitable innovators to go public. Major deals—Legend Biotech with Janssen, SinoBiopharm with Pfizer, and Hengrui with Kailera—illustrate the expanding partnership landscape. With insurance negotiations driving price cuts of up to 80 % for new PD‑1 inhibitors, Chinese drugs are becoming both affordable at home and attractive abroad. The next frontier is building dedicated global teams and new‑co structures to capture downstream profits, turning China’s once‑import‑heavy market into a net exporter of high‑value medical knowledge.
Read moreChina’s biotech scene is hitting the global stage. Suzhou‑based BoomRay Pharmaceuticals just signed an exclusive worldwide licensing agreement with drug giant Novartis for a pre‑clinical radioligand therapy. The partnership could bring BoomRay up to $900 million (about 6 billion RMB) in upfront cash, milestones and royalties, underscoring the growing confidence in Chinese nuclear‑medicine research. At the same time, Viking Therapeutics reported impressive results for its experimental weight‑loss drug VK2735, a dual GLP‑1/GIP receptor agonist. Over 21 weeks, participants shed 16‑19 % of their body weight, and those who switched to a bi‑weekly dosing schedule kept roughly 97 % of the loss after another 12 weeks. The data sparked a 36 % surge in Viking’s shares, highlighting the market’s appetite for next‑generation obesity treatments. Moderna also announced it will unveil full Phase III results for its personalized mRNA cancer vaccine (V940) combined with Merck’s Keytruda at the upcoming ESMO 2026 Congress. If the results hold up, it could validate a new therapeutic approach that pairs custom‑made neoantigen vaccines with immune‑checkpoint inhibitors. Industry analysts point to a broader trend: Chinese innovative drugs are gaining traction at international conferences, backed by supportive government policies that treat biopharma as a strategic pillar. This mix of scientific breakthroughs, big‑ticket deals and policy encouragement suggests China’s pharma sector is poised for sustained global expansion.
Read more